Close Menu

NEW YORK – Immuno-oncology diagnostic firm HalioDx said Thursday that it is collaborating with the Francophone Federation of Digestive Oncology (FFCD) to select patients for a Phase II trial testing immunotherapy with chemotherapy and bevacizumab in metastatic colorectal cancer.

HalioDx will use its Immunoscore in vitro diagnostic test to measure the host immune response at the tumor site by assessing lymphocytic infiltration to select patients for the multicenter POCHI trial.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
27
Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Jun
16
Sponsored by
Biognosys

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.

Jun
18
Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.